table of content
1 Study Coverage
1.1 Cancer Tumor Profiling Revenue in Cancer Tumor Profiling Business (2017-2022) & (US$ Million) Introduction
1.2 Global Cancer Tumor Profiling Outlook 2017 VS 2022 VS 2028
1.2.1 Global Cancer Tumor Profiling Market Size for the Year 2017-2028
1.2.2 Global Cancer Tumor Profiling Market Size for the Year 2017-2028
1.3 Cancer Tumor Profiling Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.3.1 The Market Share of United States Cancer Tumor Profiling in Global, 2017 VS 2022 VS 2028
1.3.2 The Growth Rate of Cancer Tumor Profiling Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4 Cancer Tumor Profiling Market Dynamics
1.4.1 Cancer Tumor Profiling Industry Trends
1.4.2 Cancer Tumor Profiling Market Drivers
1.4.3 Cancer Tumor Profiling Market Challenges
1.4.4 Cancer Tumor Profiling Market Restraints
1.5 Study Objectives
1.6 Years Considered
2 Cancer Tumor Profiling by Type
2.1 Cancer Tumor Profiling Market Segment by Type
2.1.1 Next-generation Sequencing (NGS)
2.1.2 Polymerase Chain Reaction (PCR)
2.1.3 Immunohistochemistry (IHC)
2.1.4 In Situ Hybridization (ISH)
2.1.5 Microarray
2.1.6 Others
2.2 Global Cancer Tumor Profiling Market Size by Type (2017, 2022 & 2028)
2.3 Global Cancer Tumor Profiling Market Size by Type (2017-2028)
2.4 United States Cancer Tumor Profiling Market Size by Type (2017, 2022 & 2028)
2.5 United States Cancer Tumor Profiling Market Size by Type (2017-2028)
3 Cancer Tumor Profiling by Application
3.1 Cancer Tumor Profiling Market Segment by Application
3.1.1 Personalized Medicine
3.1.2 Diagnostics
3.1.3 Biomarker Discovery
3.1.4 Prognostics
3.1.5 Research Applications
3.2 Global Cancer Tumor Profiling Market Size by Application (2017, 2022 & 2028)
3.3 Global Cancer Tumor Profiling Market Size by Application (2017-2028)
3.4 United States Cancer Tumor Profiling Market Size by Application (2017, 2022 & 2028)
3.5 United States Cancer Tumor Profiling Market Size by Application (2017-2028)
4 Global Cancer Tumor Profiling Competitor Landscape by Company
4.1 Global Cancer Tumor Profiling Market Size by Company
4.1.1 Top Global Cancer Tumor Profiling Companies Ranked by Revenue (2021)
4.1.2 Global Cancer Tumor Profiling Revenue by Player (2017-2022)
4.2 Global Cancer Tumor Profiling Concentration Ratio (CR)
4.2.1 Cancer Tumor Profiling Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Companies of Cancer Tumor Profiling in 2021
4.2.3 Global Cancer Tumor Profiling Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Cancer Tumor Profiling Headquarters, Revenue in Cancer Tumor Profiling Business (2017-2022) & (US$ Million) Type
4.3.1 Global Cancer Tumor Profiling Headquarters and Area Served
4.3.2 Global Cancer Tumor Profiling Companies Revenue in Cancer Tumor Profiling Business (2017-2022) & (US$ Million) Type
4.3.3 Date of International Companies Enter into Cancer Tumor Profiling Market
4.4 Companies Mergers & Acquisitions, Expansion Plans
4.5 United States Cancer Tumor Profiling Market Size by Company
4.5.1 Top Cancer Tumor Profiling Players in United States, Ranked by Revenue (2021)
4.5.2 United States Cancer Tumor Profiling Revenue by Players (2020, 2021 & 2022)
5 Global Cancer Tumor Profiling Market Size by Region
5.1 Global Cancer Tumor Profiling Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Cancer Tumor Profiling Market Size by Region (2017-2028)
5.2.1 Global Cancer Tumor Profiling Market Size by Region: 2017-2022
5.2.2 Global Cancer Tumor Profiling Market Size by Region (2023-2028)
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Cancer Tumor Profiling Market Size YoY Growth 2017-2028
6.1.2 North America Cancer Tumor Profiling Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Cancer Tumor Profiling Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Cancer Tumor Profiling Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe Cancer Tumor Profiling Market Size YoY Growth 2017-2028
6.3.2 Europe Cancer Tumor Profiling Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Cancer Tumor Profiling Market Size YoY Growth 2017-2028
6.4.2 Latin America Cancer Tumor Profiling Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Cancer Tumor Profiling Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Cancer Tumor Profiling Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 U.A.E
7 Company Profiles
7.1 Qiagen N.V.
7.1.1 Qiagen N.V. Company Details
7.1.2 Qiagen N.V. Business Overview
7.1.3 Qiagen N.V. Cancer Tumor Profiling Introduction
7.1.4 Qiagen N.V. Revenue in Cancer Tumor Profiling Business (2017-2022)
7.1.5 Qiagen N.V. Recent Development
7.2 Roche Molecular Systems Inc.
7.2.1 Roche Molecular Systems Inc. Company Details
7.2.2 Roche Molecular Systems Inc. Business Overview
7.2.3 Roche Molecular Systems Inc. Cancer Tumor Profiling Introduction
7.2.4 Roche Molecular Systems Inc. Revenue in Cancer Tumor Profiling Business (2017-2022)
7.2.5 Roche Molecular Systems Inc. Recent Development
7.3 Abott Molecular
7.3.1 Abott Molecular Company Details
7.3.2 Abott Molecular Business Overview
7.3.3 Abott Molecular Cancer Tumor Profiling Introduction
7.3.4 Abott Molecular Revenue in Cancer Tumor Profiling Business (2017-2022)
7.3.5 Abott Molecular Recent Development
7.4 Illumina Inc.
7.4.1 Illumina Inc. Company Details
7.4.2 Illumina Inc. Business Overview
7.4.3 Illumina Inc. Cancer Tumor Profiling Introduction
7.4.4 Illumina Inc. Revenue in Cancer Tumor Profiling Business (2017-2022)
7.4.5 Illumina Inc. Recent Development
7.5 NeoGenomics Laboratories
7.5.1 NeoGenomics Laboratories Company Details
7.5.2 NeoGenomics Laboratories Business Overview
7.5.3 NeoGenomics Laboratories Cancer Tumor Profiling Introduction
7.5.4 NeoGenomics Laboratories Revenue in Cancer Tumor Profiling Business (2017-2022)
7.5.5 NeoGenomics Laboratories Recent Development
7.6 HTG Molecular Diagnostic
7.6.1 HTG Molecular Diagnostic Company Details
7.6.2 HTG Molecular Diagnostic Business Overview
7.6.3 HTG Molecular Diagnostic Cancer Tumor Profiling Introduction
7.6.4 HTG Molecular Diagnostic Revenue in Cancer Tumor Profiling Business (2017-2022)
7.6.5 HTG Molecular Diagnostic Recent Development
7.7 Genomic Health Inc.
7.7.1 Genomic Health Inc. Company Details
7.7.2 Genomic Health Inc. Business Overview
7.7.3 Genomic Health Inc. Cancer Tumor Profiling Introduction
7.7.4 Genomic Health Inc. Revenue in Cancer Tumor Profiling Business (2017-2022)
7.7.5 Genomic Health Inc. Recent Development
7.8 Hologic Gen-Probe
7.8.1 Hologic Gen-Probe Company Details
7.8.2 Hologic Gen-Probe Business Overview
7.8.3 Hologic Gen-Probe Cancer Tumor Profiling Introduction
7.8.4 Hologic Gen-Probe Revenue in Cancer Tumor Profiling Business (2017-2022)
7.8.5 Hologic Gen-Probe Recent Development
7.9 BD Biosciences
7.9.1 BD Biosciences Company Details
7.9.2 BD Biosciences Business Overview
7.9.3 BD Biosciences Cancer Tumor Profiling Introduction
7.9.4 BD Biosciences Revenue in Cancer Tumor Profiling Business (2017-2022)
7.9.5 BD Biosciences Recent Development
7.10 Siemens Healthineers
7.10.1 Siemens Healthineers Company Details
7.10.2 Siemens Healthineers Business Overview
7.10.3 Siemens Healthineers Cancer Tumor Profiling Introduction
7.10.4 Siemens Healthineers Revenue in Cancer Tumor Profiling Business (2017-2022)
7.10.5 Siemens Healthineers Recent Development
7.11 Claris Life Sciences
7.11.1 Claris Life Sciences Company Details
7.11.2 Claris Life Sciences Business Overview
7.11.3 Claris Life Sciences Cancer Tumor Profiling Introduction
7.11.4 Claris Life Sciences Revenue in Cancer Tumor Profiling Business (2017-2022)
7.11.5 Claris Life Sciences Recent Development
7.12 Personal Genome Diagnostics, Inc.
7.12.1 Personal Genome Diagnostics, Inc. Company Details
7.12.2 Personal Genome Diagnostics, Inc. Business Overview
7.12.3 Personal Genome Diagnostics, Inc. Cancer Tumor Profiling Introduction
7.12.4 Personal Genome Diagnostics, Inc. Revenue in Cancer Tumor Profiling Business (2017-2022)
7.12.5 Personal Genome Diagnostics, Inc. Recent Development
7.13 Perthera, Inc.
7.13.1 Perthera, Inc. Company Details
7.13.2 Perthera, Inc. Business Overview
7.13.3 Perthera, Inc. Cancer Tumor Profiling Introduction
7.13.4 Perthera, Inc. Revenue in Cancer Tumor Profiling Business (2017-2022)
7.13.5 Perthera, Inc. Recent Development
7.14 Foundation Medicine, Inc
7.14.1 Foundation Medicine, Inc Company Details
7.14.2 Foundation Medicine, Inc Business Overview
7.14.3 Foundation Medicine, Inc Cancer Tumor Profiling Introduction
7.14.4 Foundation Medicine, Inc Revenue in Cancer Tumor Profiling Business (2017-2022)
7.14.5 Foundation Medicine, Inc Recent Development
7.15 V., Strand
7.15.1 V., Strand Company Details
7.15.2 V., Strand Business Overview
7.15.3 V., Strand Cancer Tumor Profiling Introduction
7.15.4 V., Strand Revenue in Cancer Tumor Profiling Business (2017-2022)
7.15.5 V., Strand Recent Development
7.16 ApoCell
7.16.1 ApoCell Company Details
7.16.2 ApoCell Business Overview
7.16.3 ApoCell Cancer Tumor Profiling Introduction
7.16.4 ApoCell Revenue in Cancer Tumor Profiling Business (2017-2022)
7.16.5 ApoCell Recent Development
7.17 Contextual Genomics
7.17.1 Contextual Genomics Company Details
7.17.2 Contextual Genomics Business Overview
7.17.3 Contextual Genomics Cancer Tumor Profiling Introduction
7.17.4 Contextual Genomics Revenue in Cancer Tumor Profiling Business (2017-2022)
7.17.5 Contextual Genomics Recent Development
7.18 Agendia
7.18.1 Agendia Company Details
7.18.2 Agendia Business Overview
7.18.3 Agendia Cancer Tumor Profiling Introduction
7.18.4 Agendia Revenue in Cancer Tumor Profiling Business (2017-2022)
7.18.5 Agendia Recent Development
7.19 GenScript
7.19.1 GenScript Company Details
7.19.2 GenScript Business Overview
7.19.3 GenScript Cancer Tumor Profiling Introduction
7.19.4 GenScript Revenue in Cancer Tumor Profiling Business (2017-2022)
7.19.5 GenScript Recent Development
8 Research Findings and Conclusion
9 Appendix
9.1 Research Methodology
9.1.1 Methodology/Research Approach
9.1.2 Data Source
9.2 Author Details
9.3 Disclaimer
